Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: Retrospective analysis of a multicenter study

Simple item page
dc.contributor.authorInal A.
dc.contributor.authorKos F.T.
dc.contributor.authorAlgin E.
dc.contributor.authorYildiz R.
dc.contributor.authorBerk V.
dc.contributor.authorTugba Unek I.
dc.contributor.authorColak D.
dc.contributor.authorKucukoner M.
dc.contributor.authorTamer Elkiran E.
dc.contributor.authorHelvaci K.
dc.contributor.authorGeredeli C.
dc.contributor.authorDane F.
dc.contributor.authorBalakan O.
dc.contributor.authorAli Kaplan M.
dc.contributor.authorGok Durnali A.
dc.contributor.authorHarputoglu H.
dc.contributor.authorGoksel G.
dc.contributor.authorOzdemir N.
dc.contributor.authorBuyukberber S.
dc.contributor.authorGumus M.
dc.contributor.authorOzkan M.
dc.contributor.authorBenekli M.
dc.contributor.authorIsikdogan A.
dc.date.accessioned2024-07-22T08:19:48Z
dc.date.available2024-07-22T08:19:48Z
dc.date.issued2012
dc.description.abstractPurpose: The majority of patients with pancreatic cancer present with advanced disease. Systemic chemotherapy for patients with pancreatic cancer has limited impact on overall survival (OS). Patients eligible for chemotherapy should be selected carefully. The aim of this study was to analyse prognostic factors for OS in advanced pancreatic cancer patients treated with first-line palliative chemotherapy with gemcitabine alone or gemcitabine plus cisplatin. Methods: We retrospectively reviewed 343 locally advanced or metastatic pancreatic cancer patients who were treated with gemcitabine or gemcitabine plus cisplatin as first-line chemotherapy between December 2000 and June 2011. Fifteen potential prognostic variables were chosen for analysis. Univariate and multivariate analyses were conducted to identify prognostic factors associated with OS. Univariate and multivariate statistical methods were used to determine prognostic factors. Results: Among the 15 variables of univariate analysis, 6 were identified to have prognostic significance: stage (p<0.001), cholestasis (p=0.02), weight loss, prior pancreatectomy, serum CEA level (p<0.001) and serum CA19-9 level (p<0.001). In addition, age, chemotherapy and liver metastasis were of borderline significance (p=0.06). Multivariate analysis (Cox proportional hazard model) included the 6 significant prognostic factors ofunivariate analysis and showed that stage was independent prognostic factor for OS, as were weight loss, and serum CEA level. Conclusion: Stage, weight loss, and serum CEA level were identified as important prognostic factors for OS in advanced pancreatic cancer patients. These findings may also facilitate pretreatment prediction of OS and can be used for selecting patients for treatment. © 2012 Zerbinis Medical Publications.
dc.identifier.issn11070625
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17854
dc.language.isoEnglish
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectCA-19-9 Antigen
dc.subjectCarcinoembryonic Antigen
dc.subjectCisplatin
dc.subjectDeoxycytidine
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPancreatic Neoplasms
dc.subjectPrognosis
dc.subjectProportional Hazards Models
dc.subjectRetrospective Studies
dc.subjectCA 19-9 antigen
dc.subjectcarcinoembryonic antigen
dc.subjectcisplatin
dc.subjectgemcitabine
dc.subjectadult
dc.subjectadvanced cancer
dc.subjectaged
dc.subjectarticle
dc.subjectcancer combination chemotherapy
dc.subjectcancer patient
dc.subjectcancer prognosis
dc.subjectcancer survival
dc.subjectcholestasis
dc.subjectfemale
dc.subjecthuman
dc.subjectliver metastasis
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedical record review
dc.subjectmultiple cycle treatment
dc.subjectoverall survival
dc.subjectpancreas cancer
dc.subjectpancreas resection
dc.subjectprotein blood level
dc.subjectretrospective study
dc.subjectweight reduction
dc.titlePrognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: Retrospective analysis of a multicenter study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu